BREEZE Optional Extension Phase: Long-term safety and efficacy of treprostinil dry powder inhaler (Tyvaso DPI) in pulmonary arterial hypertension

By afschroeder • August 30, 2025

Sahay S, Palevsky H, El-Kersh K, Restrepo-Jaramillo R, Bajwa AA, Desai S, Joly JM, Spikes LA, Eggert MS, Johri S, Shapiro SM, Fisher MR, Shah TG, Ramani GV, Mehta JP, Thrasher CM, Deng C, Smith P, Broderick M, Burger CD. BREEZE Optional Extension Phase: Long-term safety and efficacy of treprostinil dry powder inhaler (Tyvaso DPI) in pulmonary arterial hypertension. Respir Med. 2025 Aug 27;248:108318. doi: 10.1016/j.rmed.2025.108318. Epub ahead of print. PMID: 40882760.

Tags: Cardiology/Epi, Dry powder inhaler, exercise capacity, Prostacyclin dosing, Publications, pulmonary arterial hypertension, Treprostinil, Veterans Administration

Public Reporting of Quality and Clinical Outcomes in the Get With The Guidelines-Stroke Registry

Mullen MT, Zhao J, Jiang T, Gao Z, Buechner J, Wahab F, Seo MH, Harder B, Schwamm LH, Fonarow GC, Smith EE, Xian Y, Messé[...]

Myeloid Fmr1 deficiency in mice results in reduced serum cholesterol and altered bile pathway gene expression

Zhao X, Zhou J, Chyu KY, Erbay E, Cercek B, Shah PK, Dimayuga PC. Myeloid Fmr1 deficiency in mice results in reduced serum cholesterol and[...]

When Less Is More: Is It Time for a New Gold Standard?

Tan W, Aboulhosn J. When Less Is More: Is It Time for a New Gold Standard? Circulation. 2026 Jan 13;153(2):82-85. doi: 10.1161/CIRCULATIONAHA.125.077517. Epub 2026 Jan[...]